Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Farmers Insurance
Argus Health
Express Scripts
Fuji
Moodys
Dow
US Army
US Department of Justice

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,464,706

« Back to Dashboard

Which drugs does patent 7,464,706 protect, and when does it expire?

Patent 7,464,706 protects AFREZZA and is included in one NDA.

This patent has fifty-five patent family members in eighteen countries.
Summary for Patent: 7,464,706
Title:Unit dose cartridge and dry powder inhaler
Abstract: A dry powder inhaler having improved aerodynamic properties for diluting, dispersing, and metering drug particles for increasing the efficiency of pulmonary drug delivery to a patient is described. The inhaler comprises, in general, a housing having an air intake, an air flow-control/check-valve, a mixing section and a mouthpiece. A cartridge loaded with a single dose of medicament can be installed in the mixing section.
Inventor(s): Steiner; Solomon S. (Mount Kisco, NY), Poole; Trent A. (South Amherst, MA), Fog; Per B. (Bedford Hills, NY), Pohl; Roderike (Sherman, CT), Crick; Michael (Middlebury, CT), Feldstein; Robert (Yonkers, NY)
Assignee: MannKind Corporation (Valencia, CA)
Application Number:10/655,153
Patent Claim Types:
see list of patent claims
Delivery; Use; Device;

Drugs Protected by US Patent 7,464,706

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-001 Jun 27, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-002 Jun 27, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-003 Apr 17, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,464,706

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,215,300 Unit dose cartridge and dry powder inhaler ➤ Try a Free Trial
8,950,397 Unit dose cartridge and dry powder inhaler ➤ Try a Free Trial
9,061,111 Unit dose capsules and dry powder inhaler ➤ Try a Free Trial
7,305,986 Unit dose capsules for use in a dry powder inhaler ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,464,706

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 339981 ➤ Try a Free Trial
Austria 390944 ➤ Try a Free Trial
Australia 2004270204 ➤ Try a Free Trial
Australia 2005201843 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
QuintilesIMS
UBS
Federal Trade Commission
Merck
Daiichi Sankyo
Baxter
Johnson and Johnson
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.